newsfilter
← Latest News
GlobeNewswire·

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet